Company Update: Merck & Co Inc (NYSE:MRK) – 2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA® (pembrolizumab) to be Presented

[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced that new investigational data in 10 different types of cancer from the company’s immuno-oncology development program evaluating . . . → Read More: Company Update: Merck & Co Inc (NYSE:MRK) – 2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA® (pembrolizumab) to be Presented Similar Articles: Stock Update (NYSE:MRK): Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination With Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab), for the Treatment of Advanced Prostate Cancer Company Update: Merck & Co Inc (NYSE:MRK) – Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma Market Update: Merck & Co Inc (NYSE:MRK) – Merck to Hold First-Quarter 2015 Sales and Earnings Conference Call on April 28